Induced pluripotent stem cells from a spinal muscular atrophy patient
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy is one of the most common inherited forms of neurological disease leading to infant mortality. Patients have selective loss of lower motor neurons resulting in muscle weakness, paralysis and often death. Although patient fibroblasts have been used extensively to study spinal muscular atrophy, motor neurons have a unique anatomy and physiology which may underlie their vulnerability to the disease process. Here we report the generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy. These cells expanded robustly in culture, maintained the disease genotype and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother. This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease. As such, it represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SMA iPSC-derived motor neurons showed a higher vulnerability with reduced dendritic and axonal length.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Technologies to reprogram adult cells back to a pluripotent state, termed induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Yu et al., 2007), provide an unprecedented platform for studying human genetic disorders (Ebert et al., 2009; Mattis et al., 2015).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Ebert et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“RNA analysis from SMA iPSC-derived motor neuron demonstrates hyperactivation of the endoplasmic reticulum (ER) stress pathway due to activated unfolded SMN [49].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,151
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,451
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Neuronal specification in the spinal cord: inductive signals and transcriptional codes
Jessell, T. M. (2000) · Nature Reviews Genetics · doi:10.1038/35049541 · Cited by 2,089
Cited by
Items 101–200 of 1,000
Human pluripotent stem cells: an emerging model in developmental biology
Zhu, Z., & Huangfu, D. (2013) · Development · doi:10.1242/dev.086165 · Cited by 202
“However, prolonged cultures revealed a significant reduction in the number of motoneurons, consistent with the disease phenotype of selective motoneuron loss (Ebert et al., 2009).”
ResultCorti, S., Nizzardo, M., Simone, C., Falcone, M., Nardini, M., Ronchi, D., Donadoni, C., Salani, S., Riboldi, G., Magri, F., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004108 · Cited by 207
Omole, A. E., & Fakoya, A. O. J. (2018) · PeerJ · doi:10.7717/peerj.4370 · Cited by 204
“Loss of neurons following in vitro differentiation of spinal muscular atrophy-iPSCs was ameliorated by exposure to experimental drugs (Ebert et al., 2009).”
BackgroundAnaniev, G., Williams, E. C., Li, H., & Chang, Q. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025255 · Cited by 203
“Since then, patientspecific iPSCs have been successfully generated for several diseases [21,22,23,24], including Rett syndrome [25,26,27,28,29].”
BackgroundiPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
Okano, H., & Morimoto, S. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.01.007 · Cited by 202
Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure
Chen, X., Sun, G., Tian, E., Zhang, M., Davtyan, H., Beach, T. G., Reiman, E. M., Blurton‐Jones, M., Holtzman, D. M., & Shi, Y. (2021) · Advanced Science · doi:10.1002/advs.202101462 · Cited by 200
Zeng, H., Guo, M., Martins-Taylor, K., Wang, X., Zhang, Z., Park, J. W., Zhan, S., Kronenberg, M. S., Lichtler, A., Liu, H.-X., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011853 · Cited by 198
“These cells have the same genetic background as the patients, thus possessing tremendous potential to model the neurological diseases and generate patient-specific neurons for autogenous transplantation[28,29].”
BackgroundAdvances in Reprogramming Somatic Cells to Induced Pluripotent Stem Cells
Patel, M., & Yang, S. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9123-8 · Cited by 193
“This study demonstrates that human iPS cells can be used to model a specific pathology seen in a genetically inherited disease [20].”
BackgroundOpportunities and challenges of pluripotent stem cell neurodegenerative disease models
Sandoe, J., & Eggan, K. (2013) · Nature Neuroscience · doi:10.1038/nn.3425 · Cited by 191
Spinal Muscular Atrophy: A Clinical and Research Update
Markowitz, J. A., Singh, P., & Darras, B. T. (2012) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2011.09.001 · Cited by 188
“Pluripotent stem cells with the capacity to differentiate into motor neurons that lacked the expression of SMN1 were induced from a patient with type I spinal muscular atrophy and his mother [123,124].”
BackgroundPolyglutamine (PolyQ) Diseases: Genetics to Treatments
Fan, H.-C., Ho, L.-I., Chi, C.-S., Chen, S.-J., Peng, G.-S., Chan, T.-M., Lin, S.-Z., & Harn, H.-J. (2014) · Cell Transplantation · doi:10.3727/096368914x678454 · Cited by 192
“phy (45), and Parkinson’s disease (187), polyQ diseases”
BackgroundReprogramming Cellular Identity for Regenerative Medicine
Cherry, A. B. C., & Daley, G. Q. (2012) · Cell · doi:10.1016/j.cell.2012.02.031 · Cited by 191
Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy
Liblau, R. S., Vassalli, A., Seifinejad, A., & Tafti, M. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70218-2 · Cited by 187
Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape
Papp, B., & Plath, K. (2011) · Cell Research · doi:10.1038/cr.2011.28 · Cited by 188
Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises
Marchetto, M. C., Brennand, K. J., Boyer, L. F., & Gage, F. H. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr336 · Cited by 185
“To model SMA, iPSCs were generated from a child with a mutation in SMN (SMA type 1) and from his unaffected mother (3).”
BackgroundMethodHester, M. E., Murtha, M. J., Song, S., Rao, M., Miranda, C. J., Meyer, K., Tian, J., Boulting, G., Schaffer, D. V., Zhu, M. X., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.135 · Cited by 183
Clone- and Gene-Specific Aberrations of Parental Imprinting in Human Induced Pluripotent Stem Cells
Pick, M., Stelzer, Y., Bar-Nur, O., Mayshar, Y., Eden, A., & Benvenisty, N. (2009) · Stem Cells · doi:10.1002/stem.205 · Cited by 182
Liu, Q., Spusta, S. C., Mi, R., Lassiter, R. N. T., Stark, M. R., Höke, A., Rao, M. S., & Zeng, X. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2011-0042 · Cited by 176
Vera, E., Bosco, N., & Studer, L. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.062 · Cited by 172
Bantounas, I., Ranjzad, P., Tengku, F., Silajdžić, E., Forster, D., Asselin, M.-C., Lewis, P., Lennon, R., Plagge, A., Wang, Q., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.008 · Cited by 176
“, 2014; Ichimura and Shiba, 2017) and for modeling monogenic diseases (Ebert et al., 2009; Shi et al., 2017).”
Present and future challenges of induced pluripotent stem cells
Ohnuki, M., & Takahashi, K. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0367 · Cited by 174
Madison, J. M., Zhou, F., Nigam, A., Hussain, A., Barker, D. D., Nehme, R., van der Ven, K., Hsu, J., Wolf, P., Fleishman, M., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.7 · Cited by 179
Camnasio, S., Carri, A. D., Lombardo, A., Grad, I., Mariotti, C., Castucci, A., Rozell, B., Riso, P. L., Castiglioni, V., Zuccato, C., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.042 · Cited by 173
Yoshida, Y., & Yamanaka, S. (2010) · Circulation · doi:10.1161/circulationaha.109.881433 · Cited by 172
Human stem cells and drug screening: opportunities and challenges
Ebert, A. D., & Svendsen, C. N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3000 · Cited by 172
“Drug screening with patient-derived iPSCs Perhaps the most important and most exciting potential application of human iPSC technology for drug discovery could result from the recent demonstration that these cells can be generated from adult patients with specific disease”
BackgroundSelf-citationWang, Y., Liang, P., Lan, F., Wu, H., Lisowski, L., Gu, M., Hu, S., Kay, M. A., Urnov, F. D., Shinnawi, R., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.057 · Cited by 170
“For example, neurons from spinal muscular atrophy (27) and familial dysautonomia (28) displayed in vitro defects that could be corrected by candidate drugs, and the effect of b-blocking drugs has been evaluated for LQTS iPSCCMs (11).”
Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes
Conforti, P., Besusso, D., Bocchi, V. D., Faedo, A., Cesana, E., Rossetti, G., Ranzani, V., Svendsen, C. N., Thompson, L. M., Toselli, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715865115 · Cited by 168
“(50), where SMA patient-derived iPSCs differentiated to motor neurons showed survival and drug responses also found in patients.”
BackgroundSelf-citationDerivation of Induced Pluripotent Stem Cells from Human Peripheral Blood T Lymphocytes
Brown, M. E., Rondon, E., Rajesh, D., Mack, A., Lewis, R., Feng, X., Zitur, L. J., Learish, R. D., & Nuwaysir, E. F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011373 · Cited by 164
“Neuronal Differentiation The neural differentiation of TiPS cells was performed as previously described [29].”
MethodModeling Disease in Human ESCs Using an Efficient BAC-Based Homologous Recombination System
Song, H., Chung, S.-K., & Xu, Y. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2009.11.016 · Cited by 163
“Recent groundbreaking discovery that somatic cells can be reprogrammed into the induced pluripotent stem cells (iPSCs) with defined factors has provided tremendous potential for developing human disease models (Dimos et al., 2008; Ebert et al., 2009; Takahashi and Yamanaka, 2006).”
BackgroundDa Silveira Paulsen, B., De Moraes Maciel, R., Galina, A., Da Silveira, M. S., Souza, C. D. S., Drummond, H., Pozzatto, E. N., Junior, H. S., Chicaybam, L., Massuda, R., et al. (2012) · Cell Transplantation · doi:10.3727/096368911x600957 · Cited by 162
Neural Stem Cells: Historical Perspective and Future Prospects
Breunig, J. J., Haydar, T. F., & Rakic, P. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.005 · Cited by 160
“, 2010), Spinal muscular atrophy (Ebert et al., 2009), Huntington’s disease (Zhang et al.”
Present state and future perspectives of using pluripotent stem cells in toxicology research
Wobus, A. M., & Löser, P. (2011) · Archives of Toxicology · doi:10.1007/s00204-010-0641-6 · Cited by 159
Constructing and Deconstructing Stem Cell Models of Neurological Disease
Han, S. S. W., Williams, L. A., & Eggan, K. C. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.003 · Cited by 159
Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism
Ebrahimi-Fakhari, D., Saffari, A., Wahlster, L., Lu, J., Byrne, S., Hoffmann, G. F., Jungbluth, H., & Sahin, M. (2016) · Brain · doi:10.1093/brain/awv371 · Cited by 158
“Recent studies have described the generation of human iPSC lines from patients with a range of inherited diseases (Park et al., 2008; Ebert et al., 2009; Lee et al., 2009; Marchetto et al., 2010) and proof-of-principle screening studies for modulators of autophagy using iPSC are emerging (Maetzel…”
BackgroundYe, J.-H., Xu, Y.-J., Gao, J., Yan, S.-G., Zhao, J., Tu, Q., Zhang, J., Duan, X.-J., Sommer, C. A., Mostoslavsky, G., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.053 · Cited by 158
McGivern, J. V., Patitucci, T. N., Nord, J. A., Barabas, M. A., Stucky, C. L., & Ebert, A. D. (2013) · Glia · doi:10.1002/glia.22522 · Cited by 157
Self-citationEpigenetic therapy for Friedreich ataxia
Soragni, E., Miao, W., Iudicello, M., Jacoby, D., De Mercanti, S., Clerico, M., Longo, F., Piga, A., Ku, S., Campau, E., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24260 · Cited by 154
Induced Pluripotent Stem Cells from Individuals with Recessive Dystrophic Epidermolysis Bullosa
Tolar, J., Xia, L., Riddle, M. J., Lees, C. J., Eide, C. R., McElmurry, R. T., Titeux, M., Osborn, M. J., Lund, T. C., Hovnanian, A., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.346 · Cited by 155
“The complexity of RDEB, as evidenced by a plethora of biochemical events downstream of the Col7 pathology and by the varied phenotypes of human disease, is perhaps matched by the versatility and promise of reprogramming cell technology (Takahashi and Yamanaka, 2006b; Maherali et al., 2008b; Park et al., 2008c; Ebert e…”
BackgroundChen, H. M., DeLong, C. J., Bame, M., Rajapakse, I., Herron, T. J., McInnis, M. G., & O’Shea, K. S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.12 · Cited by 158
Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases
Marchetto, M. C. N., Winner, B., & Gage, F. H. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq159 · Cited by 152
“Partial disease modeling with spontaneous induction of a disease phenotype was reported in two young childhood-onset monogenetic diseases: spinal muscular atrophy (SMA) and familial dysautonomia (FD) (6,7).”
BackgroundResultSmith, A. S. T., Macadangdang, J. R., Leung, W. W., Laflamme, M. A., & Kim, D. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.12.002 · Cited by 169
“…platforms with which to study inheritable diseases such as long QT syndrome, amyotrophic lateral sclerosis, Down's syndrome, spinal muscular atrophy, Duchenne and Becker muscular dystrophies, and Huntington's disease (Dimos et al., 2008; Ebert et al., 2009; Itzhaki et al., 2011; Park et al., 2008).”
Human induced pluripotent stem cells and their use in drug discovery for toxicity testing
Scott, C. W., Peters, M. F., & Dragan, Y. P. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.02.020 · Cited by 171
“In addition, iPSC-derived cells that reproducibly develop a disease phenotype an be used to screen for compounds that selectively block develpment of this phenotype (Ebert et al., 2009).”
BackgroundToward clinical therapies using hematopoietic cells derived from human pluripotent stem cells
Kaufman, D. S. (2009) · Blood · doi:10.1182/blood-2009-03-191304 · Cited by 168
Chen, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093297 · Cited by 165
Cayo, M. A., Cai, J., DeLaForest, A., Noto, F. K., Nagaoka, M., Clark, B. S., Collery, R. F., Si-Tayeb, K., & Duncan, S. A. (2012) · Hepatology · doi:10.1002/hep.25871 · Cited by 148
Denton, K. R., Lei, L., Grenier, J. M., Rodionov, V., Blackstone, C. D., & Li, X.-J. (2014) · Stem Cells · doi:10.1002/stem.1569 · Cited by 162
Genome editing of human pluripotent stem cells to generate human cellular disease models
Musunuru, K. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.012054 · Cited by 147
“…have been generated and differentiated, with claims that phenotypic differences observed between the cell lines are relevant to disease (e.g. Ebert et al., 2009; Lee et al., 2009; Ye et al., 2009; Carvajal-Vergara et al., 2010; Rashid et al., 2010; Moretti et al., 2010; Swistowski et al.,…”
BackgroundApplication of Magnetic Nanoparticles to Gene Delivery
Kami, D., Takeda, S., Itakura, Y., Gojo, S., Watanabe, M., & Toyoda, M. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12063705 · Cited by 144
Opportunities for Use of Human iPS Cells in Predictive Toxicology
Anson, B. D., Kolaja, K. L., & Kamp, T. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.9 · Cited by 145
Complex Tissue and Disease Modeling using hiPSCs
Passier, R., Orlova, V., & Mummery, C. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.02.011 · Cited by 142
“These include amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and Alzheimer’s disease (AD) (Bright et al., 2015; McNeish et al., 2015; Naryshkin et al., 2014; Wainger et al., 2014).”
BackgroundSareen, D., Ebert, A. D., Heins, B. M., McGivern, J. V., Ornelas, L., & Svendsen, C. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039113 · Cited by 145
“Taken together, these data confirmed that this model was reliable and reproducible, and agreed with our previously published work [31].”
BackgroundResultInfluentialSelf-citationSpecification of neuronal and glial subtypes from human pluripotent stem cells
Liu, H., & Zhang, S.-C. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0770-y · Cited by 143
“Preliminary results indicate that some of the disease phenotypes, such as death of motor neurons, appear to occur in those from SMA iPSCs [60].”
Pluripotent stem cell-based therapy for Parkinson’s disease: Current status and future prospects
Sonntag, K.-C., Song, B., Lee, N., Jung, J. H., Cha, Y., Leblanc, P., Neff, C., Kong, S. W., Carter, B. S., Schweitzer, J., et al. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.04.005 · Cited by 143
Drug screening for human genetic diseases using iPSC models
Elitt, M. S., Barbar, L., & Tesar, P. J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy186 · Cited by 140
Almeida, S., Zhang, Z., Coppola, G., Mao, W., Futai, K., Karydas, A., Geschwind, M. D., Tartaglia, M. C., Gao, F., Gianni, D., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.007 · Cited by 140
“Indeed, iPSCs have been generated from patients with different neurodegenerative diseases (e.g., Dimos et al., 2008; Ebert et al., 2009; Soldner et al., 2009; Nguyen et al., 2011; Israel et al., 2012).”
Spinal muscular atrophy—recent therapeutic advances for an old challenge
Faravelli, I., Nizzardo, M., Comi, G. P., & Corti, S. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.77 · Cited by 138
Induction of Pluripotent Stem Cells from Human Third Molar Mesenchymal Stromal Cells*
Oda, Y., Yoshimura, Y., Ohnishi, H., Tadokoro, M., Katsube, Y., Sasao, M., Kubo, Y., Hattori, K., Saito, S., Horimoto, K., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.055889 · Cited by 137
Huang, H.-P., Chen, P.-H., Hwu, W.-L., Chuang, C.-Y., Chien, Y.-H., Stone, L., Chien, C.-L., Li, L.-T., Chiang, S.-C., Chen, H.-F., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr424 · Cited by 138
Wei, Y., Zeng, W., Wan, R., Wang, J., Zhou, Q., Qiu, S., & Singh, S. R. (2012) · European Cells and Materials · doi:10.22203/ecm.v023a01 · Cited by 149
Drew, L. J., Crabtree, G. W., Markx, S., Stark, K. L., Chaverneff, F., Xu, B., Mukai, J., Fenelon, K., Hsu, P., Gogos, J. A., et al. (2011) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2010.09.007 · Cited by 137
“In recent years a number of studies have shown successful reprogramming of somatic cells from patients affected by various nervous system diseases, including Parkinson’s disease (PD), Huntington’s disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) and Rett syndrome (Park et al., 2008; Dimos et…”
BackgroundRegulation of Embryonic and Induced Pluripotency by Aurora Kinase-p53 Signaling
Lee, D.-F., Su, J., Ang, Y.-S., Carvajal-Vergara, X., Mulero-Navarro, S., Pereira, C. F., Gingold, J., Wang, H.-L., Zhao, R., Sevilla, A., et al. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.020 · Cited by 139
“…analyses of data sets from iPSCs generated by different factors andmethods and in various species, including humans (Carvajal-Vergara et al., 2010; Ebert et al., 2009; Feng et al., 2009; Ku et al., 2010; Soldner et al., 2009; Zhang et al., 2011a), consistently revealed upregulation of Aurka…”
BackgroundHow to make spinal motor neurons
Davis-Dusenbery, B. N., Williams, L. A., Klim, J. R., & Eggan, K. (2014) · Development · doi:10.1242/dev.097410 · Cited by 140
“The two most studied MNDs are the childhood genetic disease spinal muscular atrophy (SMA) and the adultonset neurodegenerative disease amyotrophic lateral sclerosis (ALS) (Burghes and Beattie, 2009; Ling et al., 2013).”
BackgroundInfluentialTang, X., Zhou, L., Wagner, A. M., Marchetto, M. C. N., Muotri, A. R., Gage, F. H., & Chen, G. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.05.002 · Cited by 137
Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy
Al Abbar, A., Ngai, S. C., Nograles, N., Alhaji, S. Y., & Abdullah, S. (2020) · BioResearch Open Access · doi:10.1089/biores.2019.0046 · Cited by 134
“In an attempt for cell replacement therapy for neurodegenerative diseases, Ebert et al.24 generated the very first motor neurons differentiated from the diseased iPSC, in which the iPSC was derived from a patient’s skin fibroblast with spinal muscular atrophy.”
BackgroundInfluentialGenetic and Transcriptional Control of Bone Formation
Javed, A., Chen, H., & Ghori-Javed, F. Y. (2010) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2010.05.001 · Cited by 168
Dental Pulp of the Third Molar: A New Source of Pluripotent-like Stem Cells
Atari, M., Gil-Recio, C., Fabregat, M., García-Fernández, D. A., Barajas, M., Carrasco, M., Jung, H.-S., Hernández-Alfaro, F. J., Casals, N., Prósper, F., et al. (2012) · Journal of Cell Science · doi:10.1242/jcs.096537 · Cited by 135
“Multipotent cells that have a certain degree of pluripotency, because they are derived from early embryonic cells and maintained in the adult stage (Ebert et al., 2009), have been found in adult tissues, such as very small embryonic-like (VSEL) stem cells in the bone marrow.”
BackgroundChang, C.-Y., Ting, H.-C., Liu, C.-A., Su, H.-L., Chiou, T.-W., Lin, S.-Z., Harn, H.-J., & Ho, T.-J. (2020) · Molecules · doi:10.3390/molecules25082000 · Cited by 133
Ng, S.-Y., Soh, B. S., Rodriguez-Muela, N., Hendrickson, D. G., Price, F., Rinn, J. L., & Rubin, L. L. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.08.003 · Cited by 134
“To reveal disease phenotypes associated with SMA iPSCderived MNs (Corti et al., 2012; Ebert et al., 2009), we measured basal MN survival by counting ISL1, HB9, and ChAT MNs from day 28, where ChAT expression was observed (Figure 1D), to day 31.”
InfluentialSaporta, M., Dang, V., Volfson, D., Zou, B., Xie, X., Adebola, A., Liem, R. K. H., Shy, M. E., & Dimos, J. T. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.10.005 · Cited by 133
“Furthermore, disease specific phenotypes have been reported and, in some instances, corrected by pharmacological or genetic manipulations (Brennand et al., 2011; Ebert et al., 2009; Kazuki et al., 2010; Lee et al., 2009).”
BackgroundStem Cell Therapy for Cerebral Ischemia: From Basic Science to Clinical Applications
Abe, K., Yamashita, T., Takizawa, S., Kuroda, S., Kinouchi, H., & Kawahara, N. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.187 · Cited by 136
“These cells showed selective deficits in vitro Ebert et al (2009) Motor neuron via iPS Human iPS cells generate electrically active motor neurons in vitro Karumbayaram et al (2009) 6-OHDA, 6-hydroxydopamine; iPS, induced pluripotent stem.”
Sánchez‐Danés, A., Consiglio, A., Richaud, Y., Rodríguez-Pizà, I., Dehay, B., Edel, M. J., Bové, J., Memo, M., Vila, M., Raya, Á., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.054 · Cited by 138
“…of patient-specific pluripotent cells, providing valuable experimental platforms to model human disease (Dimos et al. , 2008; Park et al. , 2008a; Ebert et al. , 2009; Soldner et al. , 2009; Agarwal et al. , 2010) and opening the possibility of implementing patient-matched cell-therapy…”
Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells
Mungenast, A. E., Siegert, S., & Tsai, L.-H. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.11.010 · Cited by 127
“…glutamatergic neurons (Zeng et al., 2010), cortical neurons (Nieweg et al., 2015; Shi et al., 2012a, 2012b, 2012c), GABAergic interneurons (C.C. Liu et al., 2013; Y. Liu et al., 2013; Nieweg et al., 2015), motor neurons (Ebert et al., 2009), and hypothalamic-like neurons (Wang et al., 2015).”
BackgroundHosoyama, T., McGivern, J. V., Dyke, J. M. V., Ebert, A. D., & Suzuki, M. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0143 · Cited by 134
Self-citationSabapathy, V., & Kumar, S. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12839 · Cited by 123
Induced Pluripotent Stem Cells and Their Potential for Basic and Clinical Sciences
Ye, L., Swingen, C., & Zhang, J. J. (2013) · Current Cardiology Reviews · doi:10.2174/157340313805076278 · Cited by 168
“Spinal muscular atrophy Fibroblast [70]”
BackgroundInfluentialEmbryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice
Corti, S. P., Nizzardo, M., Nardini, M., Donadoni, C., Salani, S., Ronchi, D., Simone, C., Falcone, M., Papadimitriou, D. A., Locatelli, F., et al. (2009) · Brain · doi:10.1093/brain/awp318 · Cited by 142
“We and others have previously demonstrated that neural stem cell transplantation may have a beneficial effect on motor neuron disease phenotypes in mouse models (Corti et al., 2006, 2007; Ebert et al., 2009; Dimos et al., 2008).”
BackgroundInduced pluripotent stem cells: developmental biology to regenerative medicine
Nelson, T. J., Martinez‐Fernandez, A., & Terzic, A. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.159 · Cited by 138
“This seminal work was rapidly validated, adapted, and translated into protocols ultimately amenable for disease-specific applications”
Prè, D., Nestor, M. W., Sproul, A. A., Jacob, S., Koppensteiner, P., Chinchalongporn, V., Zimmer, M., Yamamoto, A., Noggle, S., & Arancio, O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103418 · Cited by 139
Laperle, A., Sances, S., Yucer, N., Dardov, V. J., Garcia, V. J., Ho, R., Fulton, A., Jones, M. R., Roxas, K., Avalos, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0739-1 · Cited by 132
Self-citationModeling the blood–brain barrier using stem cell sources
Lippmann, E. S., Al-Ahmad, A., Palecek, S. P., & Shusta, E. V. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-2 · Cited by 122
“hiPSCs can also be used to capture and study the phenotype of various genetic diseases [88] such as spinal muscular atrophy [89], Alzheimer’s dis-”
Belair, D. G., Whisler, J. A., Valdez, J., Velazquez, J., Molenda, J. A., Vickerman, V., Lewis, R., Daigh, C., Hansen, T. D., Mann, D. A., et al. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9549-5 · Cited by 120
“Induced pluripotent stem cells (iPSC) are a particularly promising cell source for modeling tissue development and pathologies associated with specific genetic defects, since patientderived tissues can be generated using both disease-relevant cell lines and control cell lines[19–22].”
Self-citationChemical Probes Identify a Role for Histone Deacetylase 3 in Friedreich's Ataxia Gene Silencing
Xu, C., Soragni, E., Chou, C. J., Herman, D., Plasterer, H. L., Rusche, J. R., & Gottesfeld, J. M. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.07.010 · Cited by 116
“We are currently deriving a neuronal cell model for FRDA based on human induced pluripotent stem (iPS) cells (Ebert et al., 2008), in the hope that these molecular biology approaches will be more amenable in neuronal cells.”
Therapeutic strategies for spinal muscular atrophy: SMN and beyond
Bowerman, M., Becker, C. G., Yáñez‐Muñoz, R. J., Ning, K., Wood, M. J. A., Gillingwater, T. H., & Talbot, K. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030148 · Cited by 137
“SMA was the first neurological disorder in which a disease-relevant phenotype was demonstrated in iPSC-derived motor neurons (Ebert et al., 2009).”
BackgroundThermoreversible Hyaluronic Acid‐PNIPAAm Hydrogel Systems for 3D Stem Cell Culture
Ekerdt, B. L., Fuentes, C. M., Lei, Y., Adil, M. M., Ramasubramanian, A., Segalman, R. A., & Schaffer, D. V. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800225 · Cited by 117
Engineered skeletal muscles for disease modeling and drug discovery
Wang, J., Khodabukus, A., Rao, L., Vandusen, K., Abutaleb, N., & Bursac, N. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119416 · Cited by 115
Farra, N., Zhang, W.-B., Pasceri, P., Eubanks, J. H., Salter, M. W., & Ellis, J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.180 · Cited by 118
Deriving Excitatory Neurons of the Neocortex from Pluripotent Stem Cells
Hansen, D. V., Rubenstein, J. L. R., & Kriegstein, A. R. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.006 · Cited by 119
“…disease, Huntington's disease, Down's syndrome, familial dysautonomia, Rett syndrome, and schizophrenia (Brennand et al., 2011; Dimos et al., 2008; Ebert et al., 2009; Hotta et al., 2009; Lee et al., 2009; Marchetto et al., 2010; Nguyen et al., 2011; Park et al., 2008a; Soldner et al., 2009).”
Cayo, M. A., Mallanna, S. K., Di Furio, F., Jing, R., Tolliver, L. B., Bures, M., Urick, A., Noto, F. K., Pashos, E. E., Greseth, M. D., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.01.011 · Cited by 116
“…with hepatocyte characteristics, investigators can now model heritable human diseases in culture and screen for therapeutics (Lee et al., 2009; Ebert et al., 2009; Rashid et al., 2010; Matsa et al., 2014; Robinton and Daley, 2012; Choi et al., 2013; Szkolnicka et al., 2016; Cameron et al.,…”
Wang, B., Jakus, A. E., Baptista, P. M., Soker, S., Soto-Gutierrez, A., Abecassis, M. M., Shah, R. N., & Wertheim, J. A. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0235 · Cited by 113
Ebert, A. D., Shelley, B. C., Hurley, A. M., Onorati, M., Castiglioni, V., Patitucci, T. N., Svendsen, S. P., Mattis, V. B., McGivern, J. V., Schwab, A. J., et al. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.01.009 · Cited by 109
“These iPSC lines have each been previously characterized for full reprogramming and down-regulation of exogenous transgene expression (Ebert et al., 2009; HD iPSC Consortium, 2012).”
BackgroundSelf-citationMoretti, A., Bellin, M., Jung, C. B., Thies, T., Takashima, Y., Bernshausen, A., Schiemann, M., Fischer, S., Moosmang, S., Smith, A. G., et al. (2009) · The FASEB Journal · doi:10.1096/fj.09-139477 · Cited by 124
Haridhasapavalan, K. K., Borgohain, M. P., Dey, C., Saha, B., Narayan, G., Kumar, S., & Thummer, R. P. (2019) · Gene · doi:10.1016/j.gene.2018.11.069 · Cited by 115
Xu, X., Lei, Y., Luo, J., Wang, J., Zhang, S., Yang, X., Sun, M., Nuwaysir, E. F., Fan, G.-H., Zhao, J. Y., et al. (2012) · Stem Cell Research · doi:10.1016/j.scr.2012.11.005 · Cited by 122
“Despite many attempts to use hiPS cells to model human neurodegenerative diseases for the last five years since they have been available (Brennand et al., 2010; Dimos et al., 2008; Ebert et al., 2009; Israel et al., 2012; Lee et al., 2009; Shi et al., 2012; Song et al., 2011), there are still many challenges.”
BackgroundNeural Stem Cell Biology in Vertebrates and Invertebrates: More Alike than Different?
Brand, A. H., & Livesey, F. J. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.016 · Cited by 124
Induced pluripotent stem cells: a new revolution for clinical neurology?
Mattis, V. B., & Svendsen, C. N. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70022-9 · Cited by 125
Self-citationInduced Pluripotency and Epigenetic Reprogramming
Hochedlinger, K., & Jaenisch, R. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019448 · Cited by 111
“Moreover, three promising reports showed that iPSCs derived from patients suffering from the devastating disorders SMA (Ebert et al. 2009), familial dysautonomia (Lee et al. 2009), and LEOPARD syndrome (Carvajal-Vergara et al. 2010) recapitulated the cell abnormalities in a Petri dish as they are seen in patients.”
BackgroundInfluentialBardy, J., Chen, A. K., Lim, Y. M., Wu, S., Wei, S., Weiping, H., Chan, K., Reuveny, S., & Oh, S. K. W. (2013) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2012.0146 · Cited by 111
“Because of the relative ease of generating hiPSCs from the somatic cells of patients with neurodegenerative disease, hiPSCs were used in models of complex diseases such as amyotrophic lateral sclerosis, 14 familial dysautonomia, 15 spinal muscular atrophy (SMA) 16 and Rett syndrome.”
InfluentialGeneration of Human Melanocytes from Induced Pluripotent Stem Cells
Ohta, S., Imaizumi, Y., Okada, Y., Akamatsu, W., Kuwahara, R., Ohyama, M., Amagai, M., Matsuzaki, Y., Yamanaka, S., Okano, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016182 · Cited by 111
“The lines indicate the linear equivalent and 5-fold differences on either side in gene expression levels between the two samples. doi:10.1371/journal.pone.0016182.g003 PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16182 PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16182 patient…”
BackgroundInfluentialPluripotent Stem Cells and Disease Modeling
Colman, A., & Dreesen, O. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.08.010 · Cited by 131
“Ebert et al. (2009) made iPSCs from the fibroblasts of a SMA patient and his unaffected mother.”
BackgroundJang, J., Yoo, J.-E., Lee, J., Lee, D. R., Kim, J. Y., Huh, Y. J., Kim, D., Park, C., Hwang, D., Kim, H.-S., et al. (2012) · Experimental & Molecular Medicine · doi:10.3858/emm.2012.44.3.015 · Cited by 120
“For example, a progressive degeneration of motor neurons was observed during differentiation from spinal muscular atrophy (SMA)-iPSCs (Ebert et al., 2009).”
BackgroundInfluential
Metadata
- Authors
- Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Missouri (US)
- Corresponding author
- Ebert, Allison D.
- Svendsen, Clive N.
- Venue
- Nature
- Published
- 2008-12-21
- Volume
- 457
- Issue
- 7227
- Pages
- 277-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2659408
- OpenAlex
- W2145492799
- Cited by
- 1,441
- References
- 42
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 28 · 2023: 31 · 2022: 36 · 2021: 33 · 2020: 46 · 2019: 54 · 2018: 53 · 2017: 60 · 2016: 85 · 2015: 109 · 2014: 112 · 2013: 145 · 2012: 199
- FWCI
- 58.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (T32AG027566)
- National Institute of General Medical Sciences (T32GM008396)
- National Institute of Neurological Disorders and Stroke (R01 NS41584, P01NS057778, R01NS041584)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD054413)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, motor neurons, SMN1, SMN2, dermal fibroblasts, disease modeling, neural progenitor cells, drug screening, inherited neurological diseases, Huntington's disease
- MeSH terms
- Cell Differentiation, Cell Separation, Cells, Cultured, Child, Female, Fibroblasts, Gene Expression Regulation, Humans, Male, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Cell Lineage, Pluripotent Stem Cells, Survival of Motor Neuron 1 Protein, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.